Halozyme Therapeutics $1.5B Debt Financing with The Bank of New York Mellon Trust Company, N.A.
Halozyme Therapeutics completed the sale of $1.5 billion in 1.50% Convertible Senior Notes due 2033, which included a $200 million overallotment option exercised by initial purchasers. The company used the proceeds to fund capped call transactions and to repurchase approximately $652.5 million of its existing 0.25% notes due 2027 and 1.00% notes due 2028.
- Value
- $1.5B
- Counterparty
- The Bank of New York Mellon Trust Company, N.A.
- Term
- through 2033